The House of Representatives today voted 230-192 to approve the Lower Prescription Drug Costs Now Act (H.R. 3), legislation that would make changes to the Medicare program in an effort to lower prescription drug prices. According to a legislative summary, the bill would allow the Department of Health and Human Services to negotiate prices for up to 250 drugs without competition. It also would require drug makers to pay rebates to Medicare if their prices increase faster than inflation; cap annual out-of-pocket costs for Part D beneficiaries at $2,000; and expand access to the Part D low-income subsidy and Medicare Savings Program, among other provisions.

As amended on the floor, the bill also would create an HHS grant program to help hospitals in rural and medically underserved areas start a graduate medical education program or partner with a hospital that has an existing program. Rep. Tom O’Halleran, D-Ariz., introduced the amendment.

The Senate is not expected to vote on the legislation.

Headline
AHA Board Chair Marc Boom, M.D., took the stage today to introduce AHA award winners and a town hall discussion on navigating the 2026 political landscape…
Headline
The Centers for Medicare & Medicaid Services July 1 launched the Medicare GLP-1 Bridge, a short-term demonstration program designed to provide eligible…
Headline
A blog by Noah Isserman, AHA director of health insurance and coverage policy, explains why a recent analysis by the Medicare Payment Advisory Commission…
Blog
Public
Medicare Advantage now covers more than half of eligible Medicare beneficiaries, making its impact on hospitals, health systems and patients impossible to…
Headline
The House Energy and Commerce Subcommittee on Health June 25 held a markup session on bills regarding healthcare price transparency, illicit drugs …
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services released a proposed rule June 12 seeking to codify the…